Evidence map›Paper›PMID 39719040›Full record

Observational studyBlood2025

Non-V600E BRAF mutations and treatment for hairy cell leukemia.

Evgeny Arons, Chin-Hsien Tai, Joshi Suraj, Yuelin Liu, Chi-Ping Day, Mark Raffeld, Liqiang Xi, Hong Zhou, Mory Gould, Isaac Shpilman and 9 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01087333 (A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01087333 recruitingnot on this map

A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment

TypeobservationalSponsorNational Cancer Institute (NCI)Ran2010Enrolled1,263ConditionsHairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Evgeny AronsLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Chin-Hsien TaiLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-4766-0535
Joshi SurajCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-2556-9194
Yuelin LiuCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-1051-7236
Chi-Ping DayCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-5200-2372
Mark RaffeldLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Liqiang XiLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-5033-7072
Hong ZhouLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Mory GouldLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Isaac ShpilmanLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Cristopher C OakesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Seema BhatDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.ORCID 0000-0001-7844-0856
Michael GreverDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Daniel JonesDepartment of Pathology, The Ohio State University, Columbus, OH.
Kerry RogersDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.ORCID 0000-0001-5748-7874
Hao-Wei WangLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-5408-9253
Constance M YuanLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-2601-3665
Cenk SahinalpCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Robert J KreitmanLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

abstractWe found 20 patients with an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V600E. Fourteen had 1 non-V600E BRAF mutation and 6 had V600E with 1 (n = 5) or 2 (n = 1) non-V600E BRAF comutations. This study was registered at https://clinicaltrials.gov as #NCT01087333.

Indexed as

Leukemia, Hairy CellMutationProto-Oncogene Proteins B-rafAdultAgedAged, 80 and overCase-Control StudiesFemaleHumansMaleMiddle AgedBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID39719040
PMCPMC12782980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.